Urology News and Research

Latest Urology News and Research

Hydraulic erectile prosthesis implantation in gender reassignment therapy: Study

The final step in the multidisciplinary approach of gender reassignment therapy in female-to-male transsexuals consists of the construction of a neophallus to allow the patient to void while standing and to have sexual experience after he is accustomed to his new voiding abilities. The main limiting factor is that there is no good substitute for the unique erectile tissue of the penis. The largest retrospective study by Hoebeke et al. evaluates the outcome in 129 female-to-male transsexuals after implantation of a hydraulic erectile prosthesis.

20 Jan 2010

Gently rocking embryos during IVF may improve success rates

Gently rocking embryos while they grow during in vitro fertilization (IVF) improves pregnancy rates in mice by 22 percent, new University of Michigan research shows. The procedure could one day lead to significantly higher IVF success rates in humans.

20 Jan 2010

Endo Pharmaceuticals' partners receive Paragraph IV Certification Notice regarding LIDODERM

Endo Pharmaceuticals announced today that its partners, Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. have received a Paragraph IV Certification Notice from Watson Laboratories, Inc. advising of the filing of an Abbreviated New Drug Application (ANDA) for a generic version of LIDODERM® (lidocaine topical patch 5%).

20 Jan 2010

Watson Laboratories files ANDA for Lidoderm

Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lidocaine topical patch 8% prior to the expiration of U.S. Patent No. 5,827,529.

19 Jan 2010

New procedure could lead to higher IVF success rates in humans

19 Jan 2010

New genetic risk factor for Parkinson's disease identified

An international team of doctors and human geneticists has identified a new genetic risk factor for Parkinson's disease. The institutions involved in the study were the Institute of Human Genetics of Helmholtz Zentrum München and Technische Universität München, the Neurological Clinic of Ludwig-Maximilians-Universität Munich (LMU) and the Mitochondrial Research Group of Newcastle University, Newcastle upon Tyne, UK.

18 Jan 2010

New technique can restore facial movements in paralytic patients

Surgeons from UC Davis Medical Center have demonstrated that artificial muscles can restore the ability of patients with facial paralysis to blink, a development that could benefit the thousands of people each year who no longer are able to close their eyelids due to combat-related injuries, stroke, nerve injury or facial surgery.

18 Jan 2010

Study reveals interaction of genetic and environmental factors in the pathogenesis of Parkinson's disease

"Our study reveals the interaction of genetic and environmental factors such as dietary habits in the pathogenesis of Parkinson's disease," explained Dr. Matthias Elstner of the Neurological Clinic of LMU and Helmholtz Zentrum M-nchen, lead author of the study.

18 Jan 2010

Boston Scientific commences patient enrollment in its WallFlex Biliary RX Fully Covered Stent trial

Boston Scientific Corporation today announced that the first patient has been enrolled in a clinical trial to evaluate its WallFlex® Biliary RX Fully Covered Stent for the treatment of benign bile duct strictures. This multi-center, prospective study plans to enroll 187 patients at 11 centers worldwide over the next 18 months.

17 Jan 2010

Obesity could lead to renal cell cancer: BJUI

Being obese could lead to a greater risk of developing the most common form of renal cell cancer, according to research in the January issue of the UK-based urology journal BJUI.

13 Jan 2010

Theragenics signs agreement with Core Oncology for distribution of TheraSeed palladium-103 brachytherapy seeds

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has signed an agreement with Core Oncology, Inc. for the distribution of TheraSeed® palladium-103 brachytherapy seeds.

13 Jan 2010

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

Spectrum Pharmaceuticals today announced that the second of two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target. The two trials enrolled more than 1600 patients with non-muscle invasive bladder cancer. As per the collaboration agreement with Allergan, a $1.5 million milestone payment will be paid to Spectrum Pharmaceuticals.

13 Jan 2010

Obese patients at greater risk of developing renal cell cancer

Being obese could lead to a greater risk of developing the most common form of renal cell cancer, according to research in the January issue of the UK-based urology journal BJUI.

12 Jan 2010

Obese white men with diabetes face worse outcomes following radical prostatectomy

Obese white men who have both diabetes and prostate cancer have significantly worse outcomes following radical prostatectomy than do men without diabetes who undergo the same procedure, according to research from Duke University Medical Center appearing in Cancer Epidemiology, Biomarkers & Prevention

12 Jan 2010

PET-CT imaging appears to detect cancer in patients with neurologic complications

A combined positron emission tomography-computed tomography (PET-CT) scan of the whole body appears to detect cancer in individuals with related neurologic complications more accurately than some other commonly used tests, according to a report posted online today that will appear in the March print issue of Archives of Neurology, one of the JAMA/Archives journals.

12 Jan 2010

Positive top-line results from Protox Therapeutics' Phase 2b study of PRX302 announced

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.

11 Jan 2010

Tampa Bay Partnership releases new briefs on the economic and business growth in the Tampa Bay Region

SRI International Dedicates New Tampa Bay Research Facility SRI International, one of the world's leading independent research and technology development organizations, officially opened its new 40,000-square-foot research facility located at the Port of St. Petersburg.

11 Jan 2010

Time frame for parents to begin toilet training lessons for children

Researchers at The Bristol-Myers Squibb Children's Hospital (BMSCH) at Robert Wood Johnson University Hospital (RWJUH) and UMDNJ-Robert Wood Johnson Medical School (UMDNJ-RWJMS) have completed a study that pinpoints the period between 24 and 32 months of age as most effective time frame for parents to begin toilet training lessons with their children.

9 Jan 2010

IntegraMed America plans to open new vein clinic in Columbia, Maryland

IntegraMed America, Inc., the nation’s leading manager of specialty outpatient healthcare facilities in the emerging, technology-focused medical niches of fertility and vein care, today announced plans to open a new vein clinic in Columbia, Maryland in mid 2010.

9 Jan 2010

MinuteClinic re-accredited and earns the Joint Commission's Gold Seal of Approval

MinuteClinic, the retail health care division of CVS Caremark (NYSE: CVS) and the pioneer and largest provider of retail-based medical clinics in the United States, has become the first retail clinic to be re-accredited and earn the Joint Commission's Gold Seal of Approval(TM) for consecutive evaluation periods by having demonstrated compliance with The Joint Commission's national standards for health care quality and safety.

9 Jan 2010

Urology News and Research

Latest Urology News and Research

Hydraulic erectile prosthesis implantation in gender reassignment therapy: Study

Gently rocking embryos during IVF may improve success rates

Endo Pharmaceuticals' partners receive Paragraph IV Certification Notice regarding LIDODERM

Watson Laboratories files ANDA for Lidoderm

New procedure could lead to higher IVF success rates in humans

New genetic risk factor for Parkinson's disease identified

New technique can restore facial movements in paralytic patients

Study reveals interaction of genetic and environmental factors in the pathogenesis of Parkinson's disease

Boston Scientific commences patient enrollment in its WallFlex Biliary RX Fully Covered Stent trial

Obesity could lead to renal cell cancer: BJUI

Theragenics signs agreement with Core Oncology for distribution of TheraSeed palladium-103 brachytherapy seeds

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

Obese patients at greater risk of developing renal cell cancer

Obese white men with diabetes face worse outcomes following radical prostatectomy

PET-CT imaging appears to detect cancer in patients with neurologic complications

Positive top-line results from Protox Therapeutics' Phase 2b study of PRX302 announced

Tampa Bay Partnership releases new briefs on the economic and business growth in the Tampa Bay Region

Time frame for parents to begin toilet training lessons for children

IntegraMed America plans to open new vein clinic in Columbia, Maryland

MinuteClinic re-accredited and earns the Joint Commission's Gold Seal of Approval

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Urology News and Research

Latest Urology News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in